文献速递性腺与生殖内分泌

促性腺激素治疗病理性促性腺激素缺乏男性诱导精子发生与生育的疗效

Efficacy of Gonadotropin Therapy to Induce Spermatogenesis and Fertility in Men with Pathologic Gonadotropin Deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

研究纳入99例先天性或获得性病理性促性腺激素缺乏的不育男性,1983至2024年按标准化方案接受尿源性或重组人绒毛膜促性腺激素(hCG)联合促卵泡激素(FSH)治疗。结果显示多数患者一年内获得精子输出并实现生育,女性伴侣不良生育因素是影响妊娠的最主要因素。

要点

  • 病理性促性腺激素缺乏男性经hCG/FSH治疗,多数一年内获得精子输出。
  • 女性伴侣存在不良生育因素显著延长妊娠时间并降低妊娠率。
  • 伴侣妊娠对应的中位精子浓度在无女性因素时较低,有女性因素时较高。

核心结论

  • 多数病理性促性腺激素缺乏男性经hCG/FSH治疗可在一年内获得精子输出并实现生育。
  • 女性伴侣的不良生育因素对生育结局影响最大。

研究设计与样本

  • 连续纳入99例先天性或获得性病理性促性腺激素缺乏的不育男性。
  • 1983至2024年按标准化方案接受尿源性或重组hCG联合FSH治疗。
  • 采用Kaplan-Meier和多变量Cox回归分析达到预设精子密度阈值和妊娠的时间。

主要发现

  • 男性年龄35±1岁,女性伴侣30±1岁,共进行160个治疗周期。
  • 达到精子密度>0、>2、>5、>10、>20百万/mL的比例和中位时间分别为78%(5个月)、56%(12个月)、49%(14个月)、37%(21个月)、24%(未确定)。
  • 女性伴侣存在不良生育因素是成功妊娠的主要决定因素(风险比0.20,95%CI 0.10-0.40;P<.001)。
  • 有女性不良因素时妊娠时间显著延长(15 vs 43个月;P<.0001)。
  • 伴侣妊娠对应的中位精子浓度:无女性不良因素时为2.8(0.2,52.6)百万/mL,有女性不良因素时为35.4(15.1,52.6)百万/mL。

临床怎么用

  • 对病理性促性腺激素缺乏不育男性,可采用hCG/FSH标准化方案诱导精子发生。
  • 评估生育预后时应同时评估女性伴侣的不良生育因素。
  • 治疗期间可按精子密度阈值监测反应,预期多数在一年内获得精子输出。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Gonadotropin treatment to induce spermatogenesis for gonadotropin-deficient men is the only medically treatable cause of male infertility. However, time-dependent analyses of fertility outcomes in large cohorts are lacking. We evaluated the time to, and determinants of, fertility outcomes in men with pathologic gonadotropin-deficiency undergoing gonadotropin treatment. METHODS: Consecutive infertile men (n = 99) with congenital or acquired pathologic gonadotropin deficiency were treated with urinary or recombinant human chorionic gonadotropin and FSH according to a standardized protocol between 1983 and 2024. Kaplan-Meier and multivariate Cox regression analyses examined time to prespecified sperm density thresholds and pregnancy. RESULTS: Men aged 35 ± 1 years with female partners 30 ± 1 years underwent 160 treatment cycles. The proportion (%) and median time (months) to achieve sperm thresholds of >0, >2, >5, >10, and >20 million (M) sperm/mL was 78% (5 months), 56% (12 months), 49% (14 months), 37% (21 months), and 24% (not determined), respectively. The major determinant of successful pregnancy was the presence of adverse fertility factors in the female partner (hazard ratio 0.20, 95% confidence interval 0.10-0.40; P < .001), with time to pregnancy also significantly increased by the presence of adverse female factors (15 vs 43 months; P < .0001). The median sperm concentration associated with partner pregnancy was 2.8 (0.2, 52.6) M/mL without and 35.4 (15.1, 52.6) M/mL with adverse female factors. CONCLUSION: Most men with pathologic gonadotropin deficiency treated with hCG/FSH achieve sperm output and fertility within a year, with the greatest impact on fertility outcomes being detrimental female fertility factors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gialouris JV, Conway AJ, Idan A, et al. Efficacy of Gonadotropin Therapy to Induce Spermatogenesis and Fertility in Men with Pathologic Gonadotropin Deficiency. J Clin Endocrinol Metab. 2026. PMID: 41165146. doi:10.1210/clinem/dgaf588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。